Exhibits fructose binding activity; fructose transmembrane transporter activity; and glucose transmembrane transporter activity. Involved in cellular response to fructose stimulus; fructose import across plasma membrane; and glucose transmembrane transport. Localizes to the integral component of plasma membrane and sarcolemma. Orthologous to human SLC2A5 (solute carrier family 2 member 5); INTERACTS WITH 2,3,4,7,8-Pentachlorodibenzofuran; 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran.
fructose transporter; glucose transporter type 5, small intestine; GLUT-5; solute carrier family 2 (facilitated glucose transporter) member 5; solute carrier family 2 (facilitated glucose transporter), member 5; solute carrier family 2 (facilitated glucose/fructose transporter), member 5; solute carrier family 2, facilitated glucose transporter member 5; solute carrier family 2, member 5
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose, [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SLC2A5 mRNA
Dactinomycin inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]], Dactinomycin inhibits the reaction [Fructose results in increased expression of SLC2A5 mRNA]
Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA], Glucose promotes the reaction [PAIP2 protein binds to SLC2A5 3' UTR]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SLC2A5 mRNA
Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA, N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA]
Colforsin promotes the reaction [Fructose results in increased expression of SLC2A5 mRNA], Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA]
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose more ...
Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA], Glucose promotes the reaction [PAIP2 protein binds to SLC2A5 3' UTR]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SLC2A5 mRNA
1-((1-O-octadecyl-2-O-methylglycero)phospho)-3-deoxy-myo-inositol inhibits the reaction [Fructose results in increased expression of and results in increased activity of SLC2A5 protein] more ...
Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA], Glucose promotes the reaction [PAIP2 protein binds to SLC2A5 3' UTR]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of SLC2A5 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Fructose results in increased expression of and results in increased activity of SLC2A5 protein]
Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Fructose results in increased activity of SLC2A5 protein]], Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [Fructose results in increased expression of SLC2A5 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA]
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC2A5 mRNA, [pirinixic acid co-treated with PPARA] results in decreased expression of SLC2A5 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
